BMEA - Biomea Fusion

-

$undefined

N/A

(N/A)

Biomea Fusion NasdaqGS:BMEA Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. It's lead product candidate is icovamenib, is designed to be a bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair, it is used for the treatment of menin regulated or dependent diseases such as type 1 and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Location: 900 Middlefield Road, Redwood City, CA, 94063, United States | Website: https://biomeafusion.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

28.05M

Cash

35.86M

Avg Qtr Burn

-28.38M

Short % of Float

34.95%

Insider Ownership

14.81%

Institutional Own.

56.55%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Update

BMF-219 (icovamenib) Details
Type 1 diabetes

Big Mover™

Susp. Mover™

Phase 2

Data readout

Phase 2

Initiation

Phase 1

Update

BMF-219 (icovamenib) Details
Acute myeloid leukemia, Acute lymphoblastic leukemia

Failed

Discontinued

BMF-219 (icovamenib) Details
Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma

Failed

Discontinued